Trials / Completed
CompletedNCT04710199
Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19)
Proof-of-concept Trial to Evaluate the Safety and Efficacy of Maraviroc in Severe Acute Respiratory Syndrome (SARS) Coronavirus-2 (CoV-2) Infected Patients Hospitalized for COVID-19
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Maraviroc (MVC) is a drug, very well tolerated, it has been seen that MVC has properties of modulating the immune system, exerting an anti-inflammatory effect in different diseases. In COVID-19, very high levels of inflammation occur that cause organs and systems to be damaged. MVC could reduce this inflammation achieving a better prognosis of COVID-19.
Detailed description
In this clinical trial the investigators want to evaluate if standard treatment together with Maraviroc (MVC) compared to standard treatment alone, achieves better clinical evolution in participants hospitalized for COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Maraviroc experimental group | 300-milligram dose of the drug two times daily , oral way. During 14 days. |
| OTHER | Standard treatment | It is based on the treatment protocol for hospitalized COVID-19 patients and that will depend on the clinical status of the patient. |
Timeline
- Start date
- 2021-02-23
- Primary completion
- 2021-07-08
- Completion
- 2021-07-08
- First posted
- 2021-01-14
- Last updated
- 2023-05-06
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT04710199. Inclusion in this directory is not an endorsement.